Clinical Trial Update: Awake Axillary Impella 5.5 Placement - A Feasibility Trial [NA]

View source ↗

Summary

The feasibility trial evaluating awake axillary placement of the Impella 5.5 in cardiogenic shock has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock

Drugs mentioned

• Impella 5.5 (Impella 5.5 ventricular assist device)

Snippet

Sponsor: University of Pennsylvania | Conditions: Cardiogenic Shock | NA | Status: WITHDRAWN